Advanced search
Publication Cover
OncoImmunology Volume 4, 2015 - Issue 5
Submit an article Journal homepage
717
Views
10
CrossRef citations to date
0
Altmetric
Author's View

HLA class I as a predictor of clinical prognosis and CTL infiltration as a predictor of chemosensitivity in ovarian cancer

Yoshihiko HirohashiDepartment of Pathology; Sapporo Medical University School of Medicine; Sapporo, JapanCorrespondence[email protected]
,
Toshihiko TorigoeDepartment of Pathology; Sapporo Medical University School of Medicine; Sapporo, Japan
,
Tasuku MariyaDepartment of Pathology; Sapporo Medical University School of Medicine; Sapporo, Japan;Department of Obstetrics and Gynecology; Sapporo Medical University School of Medicine; Sapporo, Japan
,
Vitaly KochinDepartment of Pathology; Sapporo Medical University School of Medicine; Sapporo, Japan
,
Tsuyoshi SaitoDepartment of Obstetrics and Gynecology; Sapporo Medical University School of Medicine; Sapporo, Japan
&
Noriyuki SatoDepartment of Pathology; Sapporo Medical University School of Medicine; Sapporo, Japan
Article: e1005507 | Received 28 Dec 2014, Accepted 30 Dec 2014, Published online: 21 May 2015

References

  • Aranda F, Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: peptide vaccines in cancer therapy. Oncoimmunology 2013; 2(12):e26621; PMID:24498550; http://dx.doi.org/10.4161/onci.26621
  • Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74:181-273; PMID:10605607; http://dx.doi.org/10.1016/S0065-2776(08)60911-6
  • Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F. MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 2007; 256:139-89; PMID:17241907; http://dx.doi.org/10.1016/S0074-7696(07)56005-5
  • Mariya T, Hirohashi Y, Torigoe T, Asano T, Kuroda T, Yasuda K, Mizuuchi M, Sonoda T, Saito T, Sato N. Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer. Cancer Immunol Res 2014; 2(12):1220-9; PMID:25324403; http://dx.doi.org/10.1158/2326-6066.CIR-14-0101
  • Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, Donato F, Wang X, Ferrone S. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res 2005; 11(1):67-72; PMID:15671529
  • Rolland P, Deen S, Scott I, Durrant L, Spendlove I. Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res 2007; 13(12):3591-6; PMID:17575223; http://dx.doi.org/10.1158/1078-0432.CCR-06-2087
  • Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, et al. HLA class I antigen processing machinery component expression and intratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 2008; 14(11):3372-9; PMID:18519766; http://dx.doi.org/10.1158/1078-0432.CCR-07-4433
  • Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102(51):18538-43; PMID:16344461; http://dx.doi.org/10.1073/pnas.0509182102
  • Shehata M, Mukherjee A, Deen S, Al-Attar A, Durrant LG, Chan S. Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy. Br J Cancer 2009; 101(8):1321-8; PMID:19755991; http://dx.doi.org/10.1038/sj.bjc.6605315
  • Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39(1):74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.